Previous 10 | Next 10 |
by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...
ArQule (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, recently closed its underwritten public offering of 10,637,500 shares of common stock, which includes 1,387,500 shares representing the over-a...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Shares of ArQule ( ARQL ) have risen by over 50% since my last update piece stated it remained a Buy with substantial upside ahead over the long term. Readers may be tempted to take full profits on the name considering the high appreciation that's taken place recently. However, when thesis str...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
ArQule ( ARQL ) is an important biotech to watch, that's because it had a huge update on a mid-stage study, showing positive results in patients with rare diseases known as PIK3CA-related Overgrowth Spectrum or PROS and proteus syndrome ((PS)). This is a solid speculative biotech. The reason w...
ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The ...
Time is the friend of the wonderful company, the enemy of the mediocre. - Warren Buffett Aside from his prowess for numbers, Warren Buffett has the excellent temperament for investment. In my view, Buffett's mega success is the cumulation of his hard work and rigorous learning. With a vora...
ArQule (NASDAQ: ARQL ) has priced its public offering of 9,250,000 common shares at $9.75 per share, for gross proceeds of ~$90.2M. More news on: ArQule, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
What stock will go up the most in 2020? We'd all like to know that one. And it's a question that's a lot easier to ask than to answer. Let's start by looking at the top 10 stocks of 2019 for clues. The No. 1 stock of 2019, Axsome Therapeutics , had a staggering 3,578% retu...
Dollar Tree (NASDAQ: DLTR) stock was pummeled in November after its earnings report resulted in the deep discounter reducing its sales outlook for the third consecutive quarter and lowering its profit forecast. Shares trade at the same level now as they did a year ago, meaning inves...
The top 10 stocks of 2019 are an interesting group. You might think tech stocks would dominate the upper echelon of equities, but you'd be wrong. As we saw in the IPO market , individual healthcare stocks actually had the strongest returns last year. Seven biotech companies made our list, inc...